BENGALURU: COVID-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced risk of infection by 80% two weeks or more after the first of two shots, according to data from a real-world U.S. study released on Monday.
The risk of infection fell 90% by two weeks after the second shot, the study of nearly 4,000 U.S. healthcare personnel and first responders found.
The results validate earlier studies that had indicated the vaccines begin to work soon after a first dose, and confirm that they also prevent asymptomatic infections.
Some countries dealing with limited vaccine supplies have pushed back schedules for second doses with the hope of getting some protection to more people. U.S. public health officials, however, continue to recommend two doses be given on the schedule authorized by regulators based on clinical trials.
The study by the U.S. Centers for Disease Control and Prevention (CDC) evaluated the vaccines' ability to protect against infection, including infections that did not cause symptoms. Previous clinical trials by the companies evaluated their vaccine's efficacy in preventing illness from COVID-19, but those studies would have missed asymptomatic infections.
The findings from of the real-world use of these messenger RNA (mRNA) vaccines also confirm the efficacy demonstrated in the large controlled clinical trials conducted before they received emergency use authorizations from the U.S. Food and Drug Administration.
The study looked at the effectiveness of the mRNA vaccines among 3,950 participants in six states over a 13-week period from Dec. 14, 2020 to March 13, 2021. About 74% had at least one shot, and tests were conducted weekly to catch any infections without symptoms.
"The authorized mRNA COVID-19 vaccines provided early, substantial real-world protection against infection for our nation's healthcare personnel, first responders, and other frontline essential workers," CDC Director Rochelle Walensky said in a statement.
The new mRNA technology is a synthetic form of a natural chemical messenger being used to instruct cells to make proteins that mirror part of the novel coronavirus. That teaches the immune system to recognize and attack the actual virus.
The CDC study comes weeks after real-world data from Israel suggested that the Pfizer/BioNTech vaccine was 94% effective in preventing asymptomatic infections.
Britain and Canada were among the countries that have allowed extended gaps between doses of up to three or four months. UK authorities said in January that data supported its decision for a 12-week gap between doses.
Pfizer and its German partner have warned that they had no evidence to prove that. In their pivotal trials, there was a three-week gap between Pfizer shots and four weeks for the Moderna vaccine.
The CDC said the study results on Monday provide reassurance that people start to develop protection from the vaccine two weeks after their first dose, although the agency reiterated that the greatest protection was seen among those who had received both recommended doses of the vaccines.
Reuters
Tue Mar 30 2021
COVID-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced risk of infection by 80 pct two weeks or more after the first of two shots. AP pic
AWANI Borneo [18/10/2024] – Perahu karam | Belanjawan 2025 | Pan Borneo dan SSLR
Tumpuan Awani Borneo 18 Oktober 2024 bersama Syaff Shukri
1. Lima peserta latihan regata dikhuatiri lemas di Sungai Sarawak.
2. Pemberian khas Sabah, Sarawak dicadang dinaikan RM600 juta.
3. Pembangunan jalan raya di Sabah, Sarawak terus diperkukuh
1. Lima peserta latihan regata dikhuatiri lemas di Sungai Sarawak.
2. Pemberian khas Sabah, Sarawak dicadang dinaikan RM600 juta.
3. Pembangunan jalan raya di Sabah, Sarawak terus diperkukuh
Tanda retak politik Filipina? Naib Presiden Sara Duterte dakwa Marcos tidak cekap
Sara Duterte mendakwa, Ferdinand Marcos Jr menjalankan pentadbirannya tanpa perancangan jelas.
AWANI Ringkas: Pembentangan Belanjawan 2025
Ikuti rangkuman berita utama yang menjadi tumpuan sepanjang hari di Astro AWANI menerusi AWANI Ringkas.
#AWANIRingkas 18 Oktober 2024 | 9 PM
Berikut merupakan rangkuman berita setakat 9 malam, 18 Oktober 2024
1️⃣ Pembentangan Belanjawan 2025
2️⃣ Sektor pendidikan
3️⃣ Sektor kesihatan
#awaniringkas
1️⃣ Pembentangan Belanjawan 2025
2️⃣ Sektor pendidikan
3️⃣ Sektor kesihatan
#awaniringkas
Belanjawan 2025: Peruntukan AI dinaikkan sebanyak RM50 juta
Kerajaan komited memperluaskan pendidikan berkaitan Kecerdasan Buatan (AI) ke semua universiti penyelidikan dengan peruntukan RM50 juta, berbanding RM20 juta tahun ini.
UAE hantar tiga lagi pesawat bersama 120 tan bantuan untuk Lubnan
UAE setakat ini telah menghantar 12 pesawat yang membawa 515 tan bekalan bantuan.
Latihan regata bertukar tragedi, lima peserta dikhuatiri lemas
Insiden melibatkan 15 peserta menggunakan satu bot untuk latihan regata. 10 individu berjaya selamatkan diri manakala lima yang lain masih hilang.
Belanjawan 2025: Nak masuk Universiti? Ini cara kerajaan bantu anda
Belanjawan MADANI memperlihatkan komitmen Kerajaan dalam meningkatkan sektor pendidikan tinggi negara.
Belanjawan 2025 sedia platform menyeluruh hadapi cabaran tahun depan - Mohamad Hasan
Langkah-langkah dalam Belanjawan 2025 juga dilihat cuba mengimbangi keperluan rakyat terutama dalam mendepani isu kos sara hidup.
Jumlah kematian di Lubnan terus meningkat
Jumlah kematian akibat serangan udara Israel di Lubnan sejak tercetusnya konflik Israel-Hizbullah pada 8 Oktober 2023 meningkat kepada 2,412.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah yang paling menjadi tumpuan sepanjang hari ini.
BioNTech kini cipta pembantu makmal AI
Pembantu makmal yang diberi nama Laila ini boleh membantu penyelidik merancang eksperimen dan meramalkan hasil mereka dengan lebih baik.
Pengeluar vaksin Biontech didakwa di mahkamah Jerman berhubung pertikaian paten
Curevac menyaman pesaingnya, Biontech untuk mendapatkan ganti rugi, dengan menuduh pengeluar utama vaksin Covid-19 itu melakukan pelanggaran paten.
Vaksin Pfizer kanak-kanak bawah 5 tahun dijangka siap akhir Februari
Pfizer dan BioNTech dijangka memohon untuk penggunaan kecemasan vaksin COVID-19 untuk kanak-kanak bawah 5 tahun.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
COVID-19: Tiga vaksin buatan Thailand tunjuk hasil memberangsangkan
Tiga vaksin COVID-19 yang dibangunkan di Thailand, termasuk satu menggunakan RNA messenger (mRNA), dijangka tersedia menjelang tahun depan.
Kadar vaksinasi Malaysia antara terpantas di dunia, lapor The Sydney Morning Herald
Ia meletakkan program vaksinasi Malaysia sebaris dengan negara-negara maju lain seperti Kanada dan Australia.
Vaksin COVID-19: Dos ketiga boleh datangkan kesan sampingan lebih buruk - CDC AS
Lebih banyak data diperlukan untuk mengetahui sama ada dos tambahan boleh meningkatkan risiko kesan sampingan.
COVID-19: Kes meningkat di Asia Tenggara bahang varian Delta
Pakar kesihatan memberi amaran kadar ujian saringan yang rendah di negara berpopulasi tinggi seperti Indonesia dan Filipina menyukarkan pengesanan angka sebenar kes jangkitan.
Varian Delta: Pfizer rancang minta kelulusan suntikan dos ketiga vaksin
Terdapat bukti wujud risiko jangkitan semula yang lebih tinggi setelah enam bulan menerima suntikan.